Literature DB >> 2543125

Replication of herpes simplex virus type 1 in differentiated human promyelocytic HL-60 cells.

C Pientong1, K Weisshart, J E Kühn, C W Knopf, R W Braun.   

Abstract

The capability of herpes simplex virus type 1 (HSV-1), strain Angelotti (ANG), to replicate in human promyelocytic HL-60 cells treated with 1,2-tetradecanoyl-phorbol-13-acetate (TPA) and dimethyl sulfoxide (DMSO) was examined. Virus titrations and infectious center assays revealed that HSV-1 ANG replicated in nontreated HL-60 cells and in HL-60 cells treated with TPA. An abortive infection was observed in DMSO-stimulated HL-60 cells. Viral DNA synthesis was detected in nontreated and TPA-treated cells, but not in DMSO-treated cells. Analysis of HSV-1 transcripts revealed that albeit the differences in pretreatment, HL-60 cells synthesized viral immediate-early (ICP4) and early (tk and pol) RNAs, whereas a late viral transcript (gC) was almost exclusively detected in nontreated and TPA-treated HL-60 cells. In line with these observations were the results obtained from studies on viral protein synthesis. The immediate-early protein ICP4 was found in all three cell types. Early (pol), delayed-early (gB), as well as late proteins (VP 5, gC) were identified in nontreated and TPA-treated cells, but only in reduced amounts in DMSO-treated cells. These data suggest a translational block of HSV replication in DMSO-treated HL-60 cells at the level of early gene expression.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2543125     DOI: 10.1016/0042-6822(89)90438-8

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  1 in total

1.  Non-muscle myosin IIA is a functional entry receptor for herpes simplex virus-1.

Authors:  Jun Arii; Hideo Goto; Tadahiro Suenaga; Masaaki Oyama; Hiroko Kozuka-Hata; Takahiko Imai; Atsuko Minowa; Hiroomi Akashi; Hisashi Arase; Yoshihiro Kawaoka; Yasushi Kawaguchi
Journal:  Nature       Date:  2010-10-14       Impact factor: 49.962

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.